Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer
Basel, 12 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present updated overall survival (OS) data from the Phase III IMbrave150 study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Media News)
Source: Roche Media News - January 12, 2021 Category: Pharmaceuticals Source Type: news

Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer
Basel, 12 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present updated overall survival (OS) data from the Phase III IMbrave150 study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - January 12, 2021 Category: Pharmaceuticals Source Type: news

Leaps-Bayer-leads-USD-million-Series-B-financing-Senti-Bio-develop-next-generation-therapies-using
Senti Bio’s gene circuit technology platform has the potential to optimize cell and gene therapies across delivery modalities and therapeutic areas / Proceeds to support platform expansion and advance multiple allogeneic CAR-NK cell therapy pipeline candidates for difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma (Source: Bayer Company News)
Source: Bayer Company News - January 6, 2021 Category: Pharmaceuticals Source Type: news

Liver cancer cells manipulate stromal cells involved in fibrosis to promote tumor growth
(Osaka University) Researchers led by Osaka University have found that liver cancer cells induce autophagy in hepatic stellate cells, causing them to produce a growth factor called GDF15 that promotes tumor growth. GDF15 was more highly expressed in tumor tissue than normal liver tissue, and patients with higher levels of GDF15 had a poorer prognosis. New therapies targeting GDF15 may help prevent the development and proliferation of hepatocellular carcinoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 6, 2021 Category: International Medicine & Public Health Source Type: news

Survival Rate for Hepatocellular Carcinoma
What Is the Survival Rate for Hepatocellular Carcinoma? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 5, 2021 Category: General Medicine Source Type: news

Fibroscan Liver Stiffness After Anti-viral Treatment for HCV Fibroscan Liver Stiffness After Anti-viral Treatment for HCV
This study investigated whether liver stiffness pre- or post-anti-viral therapy is associated with the development of decompensated cirrhosis, hepatocellular carcinoma, or death.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 16, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

New treatment options for those with liver cancer
Sharon Silverman loves to travel. But after doctors in her hometown of Pensacola, Florida, diagnosed her with hepatocellular carcinoma and told her there were no treatment options, Sharon knew she had to take one more trip. Her destination: Mayo Clinic -- where a unique radiation procedure opened the door to future adventures. Reporter DeeDee Stiepan [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 2, 2020 Category: Databases & Libraries Source Type: news

Combination therapy might improve outcomes in treatment-resistant liver cancer
(Massachusetts General Hospital) A combination cancer therapy that is effective against treatment-resistant hepatocellular carcinoma (HCC) by inhibiting tumor growth and increasing survival has been identified by researchers at Massachusetts General Hospital. The dual therapy -- which combines the multikinase inhibitor drug regorafenib to " reprogram " the tumor immune microenvironment, and programmed cell death 1 antibodies to stimulate anti-tumor immunity -- improved survival in mouse models of HCC beyond what each therapy could have achieved alone. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 30, 2020 Category: Cancer & Oncology Source Type: news

Patients Cured of HCV Still at High Liver Cancer Risk Patients Cured of HCV Still at High Liver Cancer Risk
The burden of hepatocellular carcinoma (HCC) appears likely to move from patients who currently have hepatitis C virus (HCV) infection to those who have previously been cured, a new modeling study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 26, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Rural, Urban Disparities Seen for New Liver Cancer Cases
TUESDAY, Nov. 24, 2020 -- Rates of hepatocellular carcinoma (HCC) have slowed in urban areas but continue to increase in rural areas, particularly among Black and Hispanic residents, according to a study presented at The Liver Meeting, the annual... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 24, 2020 Category: Pharmaceuticals Source Type: news

Aspirin and Statins in Chronic Hepatitis B: It's Complicated Aspirin and Statins in Chronic Hepatitis B: It's Complicated
Statins play a bigger part than aspirin in reducing risk for hepatocellular carcinoma in patients with hepatitis B, new research shows, and cirrhosis seems to cancel any beneficial effect of aspirin.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 19, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Positive Data Presented on Helio Health Liver Test for the Detection of Hepatocellular Carcinoma (HCC) Advances Product Development
New data demonstrate high accuracy of blood-based cfDNA methylation test for the detection of HCC Test has potential to outperform current screening modalities for early stage HCC within high risk populations IRVINE, Calif., Nov. 13, 2020 -- (Healthc... Diagnostics, Oncology Helio Health, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 13, 2020 Category: Pharmaceuticals Source Type: news

EGF promotes DKK1 transcription in hepatocellular carcinoma by enhancing the phosphorylation and acetylation of histone H3
The protein Dickkopf-1 (DKK1) is frequently overexpressed at the transcript level in hepatocellular carcinoma (HCC) and promotes metastatic progression through the induction of β-catenin, a Wnt signaling effector. We investigated how DKK1 expression is induced in HCC and found that activation of the epidermal growth factor receptor (EGFR) promoted parallel MEK-ERK and PI3K-Akt pathway signaling that converged to epigenetically stimulate DKK1 transcription. In HCC cell lines stimulated with EGF, EGFR-activated ERK phosphorylated the kinase PKM2 at Ser37, which promoted its nuclear translocation. Also in these cells, EG...
Source: Signal Transduction Knowledge Environment - November 10, 2020 Category: Science Authors: Niu, J., Li, W., Liang, C., Wang, X., Yao, X., Yang, R.-H., Zhang, Z.-S., Liu, H.-F., Liu, F.-Y., Pei, S.-H., Li, W.-Q., Sun, H., Fang, D., Xie, S.-Q. Tags: STKE Research Articles Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Media News - November 2, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Investor Update - November 2, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Media News - October 29, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Investor Update - October 29, 2020 Category: Pharmaceuticals Source Type: news

Rurality, Income Impact Stage at Diagnosis, Mortality in Liver Cancer
MONDAY, Oct. 26, 2020 -- Patients with hepatocellular carcinoma (HCC) from rural regions and lower-income households are more likely to have advanced-stage HCC at diagnosis and higher HCC mortality, according to a study published online Oct. 26 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 26, 2020 Category: Pharmaceuticals Source Type: news

Oncotarget: Characterization of porcine hepatocellular carcinoma for liver cancer
(Impact Journals LLC) Volume 11, Issue 28 of Oncotarget features " Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation " by Gaba et, al. which reported that reliable development of Oncopig HCC cell lines was demonstrated through hepatocyte isolation and Cre recombinase exposure across 15 Oncopigs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 10, 2020 Category: Cancer & Oncology Source Type: news

Hepatocellular Carcinoma Shows Risk Factor Shift Hepatocellular Carcinoma Shows Risk Factor Shift
The most common form of liver cancer has seen a demographic shift, with incidence highest in the Hispanic population. The good news in HCC is that rates appear to be declining among young men.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 25, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Liquid Biopsy Might Help Detect, Manage Liver Cancer in the Future Liquid Biopsy Might Help Detect, Manage Liver Cancer in the Future
Liquid biopsy could someday be useful for the early detection and clinical management of hepatocellular carcinoma (HCC), according to a new review.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 22, 2020 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

HCV-Related Liver Cancer Incidence Dropped in US Cohort HCV-Related Liver Cancer Incidence Dropped in US Cohort
The incidence of hepatocellular carcinoma declined after widespread use of direct-acting antiviral therapies to treat hepatitis C, according to findings from a large population-based study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 16, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Steatohepatitis Biomarkers and HCC After HCV Elimination Steatohepatitis Biomarkers and HCC After HCV Elimination
This study used steatohepatitis-related biomarkers to evaluate the development of hepatocellular carcinoma by patients with chronic hepatitis C who achieved SVR by DAA treatment.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 9, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Chemotherapy drug more effective when combined with microbubbles
(American Institute of Physics) Hepatocellular carcinoma is usually treated by blocking the flow of blood to the tumor to induce cancer cell death, but the common treatment, transarterial chemoembolization, is invasive and too imprecise to be a local drug delivery method. Aiming to increase the precision, researchers at Tulane University created a treatment that involves vaporizing tiny droplets of perfluorocarbon, a common organic material composed of carbon and fluorine. The method of gas embolization is published in APL Bioengineering. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2020 Category: International Medicine & Public Health Source Type: news

Sex Disparities in Presentation and Prognosis of HCC Sex Disparities in Presentation and Prognosis of HCC
A new study examines the sex disparities that exist in hepatocellular carcinoma presentation and prognosis. In what ways might these differences impact outcomes?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 2, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Yilmaz Mahshid takes office as CEO of Medivir on 14 September
STOCKHOLM, Aug. 18, 2020 -- (Healthcare Sales & Marketing Network) -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that Dr. Yilmaz Mahshid will assume his position as CEO on September 14, 2020. Uli Hacksell, who has been CEO since October 2018, wil... Biopharmaceuticals, Oncology, Personnel Medivir, hepatocellular carcinoma, liver cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 18, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Media News - August 6, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Investor Update - August 6, 2020 Category: Pharmaceuticals Source Type: news

SVR From DAA, Interferon-based Treatments for HCV and HCC Risk SVR From DAA, Interferon-based Treatments for HCV and HCC Risk
How does sustained virologic response from direct-acting antiviral and interferon-based treatments impact the risk of developing hepatocellular carcinoma?Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 5, 2020 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Pembrolizumab too costly as 2nd-line therapy of hepatocellular carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 31, 2020 Category: Drugs & Pharmacology Source Type: news

HCC in Chronic HCV Patients Who Achieved SVR HCC in Chronic HCV Patients Who Achieved SVR
Does achieving SVR with DAAs reduce the incidence of hepatocellular carcinoma in chronic hepatitis C patients, genotype IV with liver cirrhosis and advanced hepatic fibrosis?Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 17, 2020 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Sequential Systemic Treatment in Patients With HCC Sequential Systemic Treatment in Patients With HCC
This study investigated the feasibility and efficacy of sequential systemic treatments with currently available and recently approved drugs for the treatment of hepatocellular carcinoma.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 13, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Media News - July 13, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Investor Update - July 13, 2020 Category: Pharmaceuticals Source Type: news

Viral Exposure Signature Predicts Hepatocellular Carcinoma
Signature can identify hepatocellular carcinoma patients before clinical diagnosis (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 10, 2020 Category: Cancer & Oncology Tags: Gastroenterology, Infections, Oncology, Pathology, Journal, Source Type: news

Viral Exposure Signature Predicts Hepatocellular Carcinoma
FRIDAY, July 10, 2020 -- A viral exposure signature can predict hepatocellular carcinoma (HCC) risk before clinical diagnosis among at-risk patients, according to a study published online June 10 in Cell. Jinping Liu, Ph.D., of the National Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 10, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer
Basel, 18 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion031 study, evaluating Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chem otherapy (including Abraxane), met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathological complete response (pCR) for the treatment of people with early triple-negative breast cancer (TNBC), regardless of PD-L1 expression.“Tripl...
Source: Roche Media News - June 18, 2020 Category: Pharmaceuticals Source Type: news

New Blood Test May Improve Liver Cancer Screening
The test checks people for previous exposure to certain viruses that may interact with the immune system and increase the risk of hepatocellular carcinoma (HCC), according to their new study. (Source: WebMD Health)
Source: WebMD Health - June 17, 2020 Category: Consumer Health News Source Type: news

Deep learning detects HCC on contrast-enhanced MRI
A deep-learning algorithm can detect hepatocellular carcinoma (HCC) on contrast-enhanced...Read more on AuntMinnie.comRelated Reading: Functional, diffusion MRI could benefit from AI MRI identifies biomarkers for aggressive HCC subtype CE-MRI with CT extends life for patients with liver cancer AI tops recent imaging informatics highlights Beyond the black box? AI algorithm explains decisions (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 12, 2020 Category: Radiology Source Type: news

Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective
Paper proposes treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (i.e. 0, A, B,& C), specifically in relation to surgery, locoregional therapies, and systemic therapy. It also suggests strategies to modify risk during pandemic. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 12, 2020 Category: Consumer Health News Source Type: news

NIH scientists develop blood test to help improve liver cancer screening
Test can help identify people likely to develop hepatocellular carcinoma, the most common form of liver cancer (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - June 11, 2020 Category: American Health Source Type: news

NIH scientists develop blood test to help improve liver cancer screening
(NIH/National Cancer Institute) Scientists have developed a new test that can help identify people who are likely to develop hepatocellular carcinoma (HCC), the most common form of liver cancer. The approach uses a simple blood test to check for the patient's previous exposure to certain viruses. The findings were published June 10 in Cell. A study of the new approach was led by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 11, 2020 Category: Cancer & Oncology Source Type: news

FDA approves Roche ’s Tecentriq in combination with Avastin for people with the most common form of liver cancer
Basel, 2 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received p rior systemic therapy.“We’re excited that today’s approval of Tecentriq in combination with Avastin for unresectable or metastatic hepatocellular carcinoma brings a cancer immunotherapy option to people with this aggressive form of liver cancer,” said Levi Garraway, M.D., Ph....
Source: Roche Media News - June 2, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Tecentriq in combination with Avastin for people with the most common form of liver cancer
Basel, 2 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - June 2, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves Genentech ’s Tecentriq in Combination With Avastin for People With Hepatocellular Carcinoma
South San Francisco, CA -- May 29, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq ® (atezolizumab) in combination... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 29, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Atezolizumab/Bevacizumab Combination for HCC
The FDA approved atezolizumab in combination with bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Medivir Appoints Yilmaz Mahshid as New CEO
STOCKHOLM, May 26, 2020 -- (Healthcare Sales & Marketing Network) -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that its Board of Directors has appointed Yilmaz Mahshid as the new CEO of the company. Yilmaz Mahshid has long and broad experience f... Biopharmaceuticals, Oncology, Personnel Medivir AB, hepatocellular carcinoma, liver cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 26, 2020 Category: Pharmaceuticals Source Type: news

Liver cancer: Awareness of hepatitis D must be raised
(Universit é de Gen è ve) Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma. They demonstrated that people infected with Hepatitis D have up to three times the risk of developing that particularly aggressive and often fatal liver cancer compared to those infected only with Hepatitis B. These results, to be read in the Journal of Hepatology, plead for systematic screening of Hepatitis D in patients with Hepatitis B. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 18, 2020 Category: International Medicine & Public Health Source Type: news